drugset / Trial / NCT04499235
A Study to Assess the Therapeutic Effect and Safety of Adjunctive AKST4290 in Subjects With Bullous Pemphigoid
RandomizedParallel-groupDouble-blindTreatment
Summary
This study will evaluate the therapeutic effect and safety of adjunctive AKST4290 in subjects with bullous pemphigoid (BP).
Timeline
- Start
- 2020-01-30
- Primary completion
- 2021-03-29
- Completion
- 2021-04-14
Outcome
Outcome not reported
Stopped: “The study was prematurely terminated by the Sponsor due to operational challenges stemming from the coronavirus disease 2019 (COVID-19) pandemic, treatment limitations, rarity of the disease, and drug supply considerations.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LAZUCIRNON | Small molecule | 400 mg | Oral |
| Background | Mometasone furoate | Other / unclassified | — | Topical |